Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.38 |
| ▸ | DHFR | P00374 | 1/20 | 0.37 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.37 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.36 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22270709 | 0.82 | DYRK1A (0.44) | DYRK1APDE4AADORA2AADORA1TGFBR1 | |
| SCHEMBL22281484 | 0.82 | DYRK1A (0.44) | DYRK1APDE4AADORA2AADORA1TGFBR1 | |
| SCHEMBL22270681 | 0.80 | DYRK1A (0.46) | DYRK1APDE4AADORA2AADORA1TGFBR1 | |
| SCHEMBL22271044 | 0.77 | TGFBR1 (0.44) | DYRK1APDE4AADORA2AADORA1TGFBR1 | |
| SCHEMBL22270744 | 0.76 | DYRK1A (0.44) | DYRK1APDE4AADORA2AADORA1TGFBR1 | |
| SCHEMBL22271109 | 0.75 | DYRK1A (0.41) | DYRK1APDE4ATGFBR1LRRK2SCN5A | |
| SCHEMBL22271063 | 0.72 | DYRK1A (0.44) | DYRK1APDE4AADORA2AADORA1TGFBR1 | |
| SCHEMBL22270706 | 0.70 | DYRK1A (0.43) | DYRK1APDE4AADORA2AADORA1TGFBR1 | |
| SCHEMBL22270682 | 0.65 | TGFBR1 (0.49) | DYRK1AADORA2AADORA1TGFBR1CDK5 | |
| SCHEMBL24245238 | 0.65 | DYRK1A (0.38) | DYRK1APDE4ATGFBR1SCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3686199-B9 | FUSED RING DERIVATIVE AS A2A RECEPTOR INHIBITOR | CSTONE PHARMACEUTICALS SUZHOU CO LTD (CN) | 2022-12-07 | — | — | EP | disclosed |
| US-11312715-B2 | Fused ring derivative as A2A receptor inhibitor | CSTONE PHARMACEUTICALS (SUZHOU) CO., LTD. (CN) | 2022-04-26 | — | — | US | disclosed |
| US-20200239465-A1 | FUSED RING DERIVATIVE AS A2A RECEPTOR INHIBITOR | CSTONE PHARMACEUTICALS (SHANGHAI) CO., LTD. (CN) | 2020-07-30 | — | — | US | disclosed |
| EP-3686199-A1 | FUSED RING DERIVATIVE AS A2A RECEPTOR INHIBITOR | CSTONE PHARMACEUTICALS (SUZHOU) CO., LTD. (CN) | 2020-07-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11312715-B2 | Fused ring derivative as A2A receptor inhibitor | ADORA2A, ADORA2B, ADORA1 | DYRK1A 1011/4885PDE4A 529/4885ADORA2A 1/4885 |
| US-20200239465-A1 | FUSED RING DERIVATIVE AS A2A RECEPTOR INHIBITOR | ADORA2A, ADORA2B, ADORA1 | DYRK1A 1011/4885PDE4A 529/4885ADORA2A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.